The Case for Routine Genotyping in Dual-Antiplatelet Therapy

This publication has 15 references indexed in Scilit:

• Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement
  Circulation, 2010
• Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
  JAMA, 2009
• Cytochrome P-450 Polymorphisms and Response to Clopidogrel
  New England Journal of Medicine, 2009
• Genetic Determinants of Response to Clopidogrel and Cardiovascular Events
  New England Journal of Medicine, 2009
• Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
  The Lancet, 2009
• Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring to Prevent Acute and Subacute Stent Thrombosis
  The American Journal of Cardiology, 2008
• Pharmacogenomic Biomarker Information in Drug Labels Approved by the United States Food and Drug Administration: Prevalence of Related Drug Use
  Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2008
• Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
  New England Journal of Medicine, 2007
• Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y12Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes
  Journal of the American College of Cardiology, 2007
• Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
  Blood, 2006